| Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Common Share |
A reconciliation of the numerator and denominator used in the calculation of basic and diluted net income (loss) per share is as follows (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | | | Three months ended September 30, | | Nine Months Ended September 30, | | 2026 | | 2025 | | 2026 | | 2025 | | | | Numerator (basic and diluted): | | | | | | | | | | | Net income (loss) | $ | 11,290 | | | $ | 621 | | | $ | (17,577) | | | $ | (10,527) | | | | | Denominator: | | | | | | | | | | | Weighted-average shares outstanding for basic net income (loss) per share | 180,941,748 | | | 163,649,932 | | | 174,800,967 | | | 158,559,467 | | | | | Effect of dilutive securities: | | | | | | | | | | | RSUs | 5,675,998 | | | 9,829,642 | | | — | | | — | | | | | Stock Options | 1,746,477 | | | 2,041,961 | | | — | | | — | | | | | Warrants | 79,307 | | | 2,095,772 | | | — | | | — | | | | | Convertible Notes | 1,480,502 | | | — | | | — | | | — | | | | | Weighted-average shares outstanding for diluted net income (loss) per share | 189,924,032 | | | 177,617,307 | | | 174,800,967 | | | 158,559,467 | | | |
The following potentially dilutive securities were excluded from the computation of diluted weighted average common shares outstanding due to their anti-dilutive effect: | | | | | | | | | | | | | | | | | | | | | | | | | | | Three months ended September 30, | | Nine Months Ended September 30, | | 2026 | | 2025 | | 2026 | | 2025 | | | | Shares to be issued upon conversion of Convertible Notes | — | | | 10,971,895 | | | — | | | 10,971,895 | | | | RSUs | — | | | — | | | 9,245,814 | | | 13,776,105 | | | | | Stock Options | — | | | — | | | 6,925,293 | | | 5,765,600 | | | | | Warrants | — | | | — | | | 125,999 | | | 2,664,470 | | | | | | | | | | | | | | | Total anti-dilutive securities excluded from EPS computation | — | | | 10,971,895 | | | 16,297,106 | | | 33,178,070 | | | |
|